[{"id":"97308bd2-983a-4c51-b306-4acc6a3f68ec","acronym":"KEYNOTE A60","url":"https://clinicaltrials.gov/study/NCT04332653","created_at":"2021-01-18T20:58:47.509Z","updated_at":"2025-02-25T16:10:08.704Z","phase":"Phase 1/2","brief_title":"NT-I7 (Efineptakin Alfa) in Combination with Pembrolizumab in Participants with Advanced Solid Tumors","source_id_and_acronym":"NCT04332653 - KEYNOTE A60","lead_sponsor":"NeoImmuneTech","biomarkers":" BRAF • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation • BRAF mutation • ALK translocation","tags":["BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • BRAF mutation • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Hyleukin-7 (efineptakin alfa)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 215","initiation":"Initiation: 06/10/2020","start_date":" 06/10/2020","primary_txt":" Primary completion: 11/05/2024","primary_completion_date":" 11/05/2024","study_txt":" Completion: 12/20/2024","study_completion_date":" 12/20/2024","last_update_posted":"2024-10-07"},{"id":"b7e56290-6b1a-48dc-8f8b-3b38875c7932","acronym":"GENUINE","url":"https://clinicaltrials.gov/study/NCT05286060","created_at":"2022-03-18T12:53:37.680Z","updated_at":"2024-07-02T16:34:26.476Z","phase":"Phase 2","brief_title":"Trial of the Combination of GX-188E Vaccination, GX-I7 and Pembrolizumab in Patients With Advanced, Resectable HPV Type 16 and/or 18 Positive Head and Neck Cancer","source_id_and_acronym":"NCT05286060 - GENUINE","lead_sponsor":"Yonsei University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Papitrol (tirvalimogene teraplasmid) • Hyleukin-7 (efineptakin alfa)"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 03/01/2022","start_date":" 03/01/2022","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-06-13"},{"id":"51b4383b-afa9-436e-b1d7-aa41de7384ef","acronym":"","url":"https://clinicaltrials.gov/study/NCT04984811","created_at":"2021-08-02T15:53:19.407Z","updated_at":"2024-07-02T16:35:16.421Z","phase":"Phase 2","brief_title":"NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC","source_id_and_acronym":"NCT04984811","lead_sponsor":"NeoImmuneTech","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Hyleukin-7 (efineptakin alfa)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 83","initiation":"Initiation: 11/03/2021","start_date":" 11/03/2021","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2024-03-05"},{"id":"674c8cd6-b35c-4537-8285-c943d6bf233f","acronym":"KEYNOTE-899","url":"https://clinicaltrials.gov/study/NCT03752723","created_at":"2021-01-18T18:26:13.363Z","updated_at":"2025-02-25T16:08:38.422Z","phase":"Phase 1/2","brief_title":"Study of GX-I7 in Combination With Pembrolizumab in Refractory or Relapsed (R/R) TNBC Subjects(GX-I7-CA-006/KEYNOTE-899)","source_id_and_acronym":"NCT03752723 - KEYNOTE-899","lead_sponsor":"Genexine, Inc.","biomarkers":" HER-2 • ER • PGR","pipe":"","alterations":" ","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cyclophosphamide • Hyleukin-7 (efineptakin alfa) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 84","initiation":"Initiation: 03/27/2019","start_date":" 03/27/2019","primary_txt":" Primary completion: 05/11/2023","primary_completion_date":" 05/11/2023","study_txt":" Completion: 05/11/2023","study_completion_date":" 05/11/2023","last_update_posted":"2024-03-05"},{"id":"d6d10093-3f56-4d6a-b230-8bbd9e5b7bfd","acronym":"","url":"https://clinicaltrials.gov/study/NCT03687957","created_at":"2021-12-02T23:53:46.042Z","updated_at":"2024-07-02T16:35:23.583Z","phase":"Phase 1/2","brief_title":"rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temzolomide","source_id_and_acronym":"NCT03687957","lead_sponsor":"Washington University School of Medicine","biomarkers":" IDH1 • MGMT","pipe":" | ","alterations":" IDH1 R132H • IDH wild-type • IDH1 R132","tags":["IDH1 • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132H • IDH wild-type • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Hyleukin-7 (efineptakin alfa)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 01/04/2019","start_date":" 01/04/2019","primary_txt":" Primary completion: 01/31/2032","primary_completion_date":" 01/31/2032","study_txt":" Completion: 01/31/2032","study_completion_date":" 01/31/2032","last_update_posted":"2024-01-12"},{"id":"e287b7f7-e014-48e2-9282-b4b1f1b1dc60","acronym":"","url":"https://clinicaltrials.gov/study/NCT03513952","created_at":"2021-01-18T17:17:53.265Z","updated_at":"2024-07-02T16:35:26.918Z","phase":"Phase 2","brief_title":"Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma","source_id_and_acronym":"NCT03513952","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • IFNG • CD4","pipe":" | ","alterations":" PD-L1 expression • IFNG expression","tags":["PD-L1 • IFNG • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • IFNG expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • CYT107"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 47","initiation":"Initiation: 06/05/2019","start_date":" 06/05/2019","primary_txt":" Primary completion: 09/30/2023","primary_completion_date":" 09/30/2023","study_txt":" Completion: 10/22/2024","study_completion_date":" 10/22/2024","last_update_posted":"2023-12-06"},{"id":"522ce461-bd5b-48fe-83ce-bfdef14e9b4b","acronym":"GEN001-201","url":"https://clinicaltrials.gov/study/NCT05419362","created_at":"2022-06-15T16:54:51.189Z","updated_at":"2025-02-25T16:17:49.248Z","phase":"Phase 2","brief_title":"GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric Cancer","source_id_and_acronym":"NCT05419362 - GEN001-201","lead_sponsor":"Genome \u0026 Company","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • GEN-001"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 04/07/2022","start_date":" 04/07/2022","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-10-17"},{"id":"21f8bb16-844c-42fc-ae99-b94057a6b65f","acronym":"TRINITY","url":"https://clinicaltrials.gov/study/NCT05280457","created_at":"2022-03-15T18:52:58.634Z","updated_at":"2024-07-02T16:35:52.113Z","phase":"Phase 2","brief_title":"HPV 16-positive and/or HPV 18-positive Recurrent and/or For Patients With Metastatic Head and Neck Cancer to Evaluate GX-188E DNA Vaccination, GX-I7 and Nivolumab Combination Therapy","source_id_and_acronym":"NCT05280457 - TRINITY","lead_sponsor":"Yonsei University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Papitrol (tirvalimogene teraplasmid) • Hyleukin-7 (efineptakin alfa)"],"overall_status":"Recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 04/15/2022","start_date":" 04/15/2022","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2023-03-28"},{"id":"06cedc2c-5fd9-4935-a1db-659225305def","acronym":"","url":"https://clinicaltrials.gov/study/NCT05079503","created_at":"2021-10-15T14:53:04.668Z","updated_at":"2024-07-02T16:36:22.855Z","phase":"","brief_title":"Gut Microbiome and Its Immune Modulation in Locally Advanced Rectal Cancer","source_id_and_acronym":"NCT05079503","lead_sponsor":"Korean Cancer Study Group","biomarkers":" CD8 • CD4","pipe":"","alterations":" ","tags":["CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GEN-001"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 12/15/2021","start_date":" 12/15/2021","primary_txt":" Primary completion: 08/30/2023","primary_completion_date":" 08/30/2023","study_txt":" Completion: 01/30/2024","study_completion_date":" 01/30/2024","last_update_posted":"2021-10-15"},{"id":"c1c8a21f-267f-4773-bc59-4b9d7ab6b8c3","acronym":"GBM","url":"https://clinicaltrials.gov/study/NCT03619239","created_at":"2021-01-18T17:47:07.454Z","updated_at":"2024-07-02T16:36:38.902Z","phase":"Phase 1b","brief_title":"Dose-escalation Study to Evaluate the Safety and Tolerability of GX-I7 in Patients With Glioblastoma","source_id_and_acronym":"NCT03619239 - GBM","lead_sponsor":"Genexine, Inc.","biomarkers":" IL7","pipe":"","alterations":" ","tags":["IL7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hyleukin-7 (efineptakin alfa)"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 06/20/2018","start_date":" 06/20/2018","primary_txt":" Primary completion: 09/25/2020","primary_completion_date":" 09/25/2020","study_txt":" Completion: 09/25/2020","study_completion_date":" 09/25/2020","last_update_posted":"2020-11-10"},{"id":"be0663b5-2478-4403-8fcb-c2a5b443dd4a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01881867","created_at":"2021-01-18T08:26:13.034Z","updated_at":"2024-07-02T16:36:58.281Z","phase":"Phase 2","brief_title":"CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer","source_id_and_acronym":"NCT01881867","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" IFNG • CSF2 • PSAP","pipe":"","alterations":" ","tags":["IFNG • CSF2 • PSAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CYT107"],"overall_status":"Completed","enrollment":" Enrollment 54","initiation":"Initiation: 09/10/2013","start_date":" 09/10/2013","primary_txt":" Primary completion: 05/15/2017","primary_completion_date":" 05/15/2017","study_txt":" Completion: 01/02/2018","study_completion_date":" 01/02/2018","last_update_posted":"2019-07-09"}]